Bone Biologics Corporation (BBLG)

1.5251 -0.0749 (-4.68%) At close: 04:00PM EDT

Bone Biologics Corporation

2 Burlington Woods Drive
Suite 100
Burlington, MA 01803
United States
781 552 4452
https://www.bonebiologics.com

Sector(s): Healthcare
Industry: Medical Devices
Full-time employees: 2

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Jeffrey Frelick	CEO & President	325k	N/A	1966
Ms. Deina H. Walsh	Chief Financial Officer	212.5k	N/A	1964
Dr. Shun'ichi Kuroda	Co-Founder & Member of Scientific Advisory Board	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.

Corporate governance

Bone Biologics Corporation’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.